Quench Bio

About:

Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.

Twitter/X: QuenchBio

Top Investors: RA Capital Management, AbbVie, Atlas Venture, Arix Bioscience

Description:

Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enabling patients to get relief from inflammatory diseases.

Total Funding Amount:

$50M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2018-01-01

Contact Email:

info(AT)quenchbio.com

Founders:

Mark J. Tebbe, Mike Nolan

Number of Employees:

1-10

Last Funding Date:

2020-01-27

IPO Status:

Private

Industries: